2023 World Conference on Lung Cancer (Posters)-EP11.01. SPD-CD40L Prevents Tumor Growth via Recruitment of Immune Cells to the Tumor Microenvironment

EP11.01. SPD-CD40L Prevents Tumor Growth via Recruitment of Immune Cells to the Tumor Microenvironment - PDF(Slides)

Pdf Summary

The study focuses on the potential use of SPD-CD40L, a chimeric protein, to prevent tumor growth by recruiting immune cells to the tumor microenvironment (TME). The researchers hypothesized that the presence of pro-inflammatory adjuvants in the TME would induce anti-tumor immune responses. <br /><br />The study first demonstrates that SPD-CD40L activates dendritic cells, an important component of the immune system, through the crosslinking of CD40. This activation is characterized by the upregulation of CD80, CD86, and class I MHC molecules. <br /><br />Next, the researchers investigated the effects of SPD-CD40L on tumor growth. They spliced SPD-CD40L into a doxycycline (Dox) responsive promoter and transfected it into B16 tumor cells. Mice were then treated with or without doxycycline and followed for tumor growth. The results showed that the presence of SPD-CD40L in the TME inhibited tumor growth, with a higher percentage of tumor-free mice compared to control groups. <br /><br />Furthermore, tumors removed from the experiment were stained and analyzed. Immune cell infiltration was observed in mice treated with SPD-CD40L and doxycycline, indicating the recruitment of immune cells to the tumor. <br /><br />In conclusion, SPD-CD40L was found to activate dendritic cells and recruit immune cells to the tumor microenvironment, resulting in the inhibition of tumor growth. These findings suggest that SPD-CD40L may have potential as an immunotherapy for cancer treatment by enhancing anti-tumor immune responses.

Asset Subtitle

Gregory Holt

Meta Tag

Speaker Gregory Holt

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

SPD-CD40L

chimeric protein

tumor growth prevention

immune cells recruitment

tumor microenvironment

pro-inflammatory adjuvants

anti-tumor immune responses

dendritic cells activation

tumor growth inhibition

immunotherapy for cancer treatment